P790: THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)

P790: THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)

Bibliographic Details
Main Authors:	X. Ye, J. Huang
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846044.98500.37

Similar Items

LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome
by: Katja Kaastrup, et al.
Published: (2023-05-01)

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes
by: Amalie Bach Nielsen, et al.
Published: (2022-05-01)

Idiopathic cytopenia of undetermined significance and systemic lupus erythematosus
by: Romelia Pinheiro Goncalves, et al.
Published: (2013-01-01)

Acquired erythropoietic uroporphyria associated with clonal cytopenia of undetermined significance
by: Leah A. Swanson, MD, et al.
Published: (2023-02-01)

Diagnostic Approach, Clinical Implications and Management of Clonal Cytopenia of Undetermined Significance
by: Ioannis Chanias, et al.
Published: (2022-12-01)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
by: LI Marissa, et al.
Published: (2023-08-01)

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
by: Zhuoer Xie, et al.
Published: (2021-03-01)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Annika Kasprzak, et al.
Published: (2022-04-01)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
by: KS G&ouml;tze, et al.
Published: (2009-10-01)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
by: Oriol Calvete, et al.
Published: (2023-02-01)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
by: Xiaoqing Xie, et al.
Published: (2021-12-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
by: Tamara Borgonovo, et al.
Published: (2005-12-01)

Membranous glomerulonephritis in a patient with myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia
by: Kwang Il Ko, et al.
Published: (2013-09-01)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
by: Sabine Blum, et al.
Published: (2021-09-01)

Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
by: Rong He, et al.
Published: (2022-01-01)

Xanthogranuloma necrobioticum in the course of monoclonal gammopathy of undetermined significance and idiopathic neutropenia
by: Urszula Maińska, et al.
Published: (2023-04-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study
by: Kira-Lee Koster, et al.
Published: (2023-09-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
by: Broojerdi, Mohadese Hashem, et al.
Published: (2012)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
by: Mohamed Amine Bekadja, et al.
Published: (2023-04-01)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
by: Michele Stanchina, et al.
Published: (2021-04-01)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

TELOMERE LENGHT AND CYTOPENIAS: ANALYSIS OF CHILDREN REFERRED TO BRAZILIAN COOPERATIVE GROUP OF CHILDHOOD MYELODYSPLASTIC SYNDROME
by: Rafael Balceiro, et al.
Published: (2023-12-01)

CLINICAL AND HEMATOLOGICAL PROFILE OF CHILDREN WITH CYTOPENIAS REFERRED TO THE BRAZILIAN COOPERATIVE GROUP OF PEDIATRIC MYELODYSPLASTIC SYNDROME
by: Caroline Ramalho Rosa, et al.
Published: (2023-12-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies
by: Artur Słomka, et al.
Published: (2024-01-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
by: Chen, J, et al.
Published: (2022)

The Correlation of Age with Prognosis of Atypia of Undetermined Significance and Follicular Lesion of Undetermined Significance in Thyroid Nodules
by: Kaliszewski K, et al.
Published: (2021-04-01)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
by: Botezatu, L, et al.
Published: (2016)

P108: Myelodysplastic syndrome (MDS) detected by germline genetic testing for hereditary cancer
by: Larissa Peck, et al.
Published: (2024-01-01)

Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry
by: Annika Kasprzak, et al.
Published: (2024-02-01)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
by: Anson Snow, et al.
Published: (2022-07-01)

Therapy related myelodysplastic syndrome (t-MDS) in childhood Acute lymphoblastic leukemia- an interesting observation
by: Kavita Gaur, et al.
Published: (2022-01-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
by: Myrna Candelaria-Hernández, et al.
Published: (2017-06-01)

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
by: Daisuke Okamura, et al.
Published: (2014-01-01)

REFRACTORY CYTOPENIA OF CHILDHOOD: CLINICAL FEATURES, PATHOLOGIC FINDINGS AND EXPERIENCE OF BRAZILIAN COOPERATIVE GROUP OF PEDIATRIC MYELODYSPLASTIC SYNDROME
by: Caroline Ramalho Rosa, et al.
Published: (2023-12-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Efficace, F, et al.
Published: (2024)